All News

Preventing recurrent violent injury has always been an important component of public health approach to interpersonal violence. However, prior studies have done very little to highlight the true incidence of recurrent violent injury.

Almost one-fourth of low-income adults in 3 states (Arkansas, Kentucky, and Texas) have experienced changes in health insurance coverage, known as “churning,” since the passage of the Affordable Care Act.

Precision medicine is an emerging approach to disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.

Between 2005 and 2013, the United States prescription drug market grew at an average annual pace of 1.8%. The same market experienced a dramatic growth rate in 2014 of 11.5%.

Data released by the CDC today indicate that while breast cancer deaths are on the decline, black women still have worse outcomes than white women. The report also noted disparate trends in breast cancer incidence among different races and age groups.

In creating the final rule for the Medicare Access and CHIP Reauthorization Act, CMS did an excellent job listening to, and responding to, a vast array of comments from healthcare stakeholders.

About half of Americans have low health literacy and struggle to find and use health information, which is associated with negative outcomes, including overall poorer health.

This week, the top stories in managed care included HHS releasing the final rule for the Medicare Access and CHIP Reauthorization Act, a commentary on the downside of drug coupons, and the World Health Organization called on countries to enact a soda tax.

HHS has issued its final rule on the Medicare Access and CHIP Reauthorization Act (MACRA), which reforms the Medicare payment system as part of the shift to value-based care. Here are 5 things to know about the final rule.

Coverage of our peer-reviewed research in the healthcare and mainstream press.

What we’re reading, October 14, 2016: Senator Bernie Sanders will speak in support of a California bill that would require the state to pay less for prescription drugs; HHS reaches out to consumers ahead of open enrollment period; and CDC warns that contaminated heart surgery devices could cause severe infections.

Rates of liver cancer have steadily climbed alongside rising rates of obesity and diabetes, leading researchers to investigate links among the conditions.

HHS has finalized the landmark Medicare Access and CHIP Reauthorization Act (MACRA), which reforms payment for Medicare providers and replaced the sustainable growth rate formula.

More transparency and validation is needed for consumer-based benchmarking methods, such as US News & World Report's Best Hospitals rankings, according to a new study.

The cost of an intravenous drug used to treat lead poisoning has skyrocketed after a 2700% price increase by Valeant Pharmaceuticals. Experts worry that its high price and the lack of alternatives will place it out of reach for hospitals that need it. This is not the first time Valeant has been criticized for its price-raising practices.

Gaining too much weight during pregnancy can bring serious health consequences.

What we’re reading, October 13, 2016: researchers, Alzheimer’s patients, and their families anxiously await the results of a clinical trial that could help slow the disease’s progress; many breast cancers detected by mammograms are overtreated even though they likely would not be fatal on their own; stock prices fall for Humana and Cigna as CMS says a minority of their patients are in plans rated 4 stars or higher.

The partnership is expected to improve the quality of care and the overall care experience for Aetna members who seek care at Regional Cancer Care Associates (RCCA) clinics in New Jersey and Maryland.

Radiomic combines imaging and computational technologies and can identify patients with recurrent glioblastoma who may benefit from using angiogenesis inhibitors.

As the public grows increasingly outraged over the rising cost of prescription drugs, the cost of hospital inpatient drugs has been overlooked. According to a new report, inpatient drug spending increased 23.4% annually between 2013 and 2015.

A survey by Avalere Health found that only 19% of drug makers publicly post policies about their compassionate use programs.

The pay-for-performance deal comes as Januvia faces increased competition from newer drug classes, especially SGLT2 inhibitors and GLP-1 receptor agonists.

What we're reading, October 12, 2016: a US senator calls for a limit to prescription fentanyl; healthcare costs aren't skyrocketing, despite claims; IBM's Watson will identify cancer treatment and clinical trials for IBM employees.

A pilot analysis published online in JAMA Cardiology has concluded that Twitter offers promise as a data source for studying public communication about cardiovascular disease.

A study from Tufts University School of Medicine found that at age 10, obesity rates among children on the autism spectrum are not that much higher than children outside the spectrum, but rates diverge sharply as children get older.

A retrospective study in breast cancer patients suggests that patients can lower their out-of-pocket costs by speaking with their oncologist about alternate treatments that may be equally effective and understanding the drug coverage policy of their insurance plan.

Innovation in oncology treatments has reduced the mortality rate for cancer, but it comes at a price. At the 5th Annual Patient-Centered Oncology Care, experts will discuss cost-sharing models, as well as updates in cancer care treatment, such as precision medicine and immuno-oncology.

The study found that in diabetic mice, a common sweetener appears to travel straight to the liver, where it causes fat to accumulate.

Coupons seem like a good deal for consumers, but they mask the true costs of drugs and force up premiums for everyone.

Medicare beneficiaries still face huge out-of-pocket expenses because of uncapped cost sharing in the catastrophic coverage phase. This is especially true for beneficiaries who take specialty drugs.